Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Meta-Analysis of Microrna Expression Profiling Studies in Heart Failure Publisher Pubmed



Gholaminejad A1 ; Zare N2 ; Dana N2 ; Shafie D3 ; Mani A4 ; Javanmard SH2, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Regenerative Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical, Isfahan, Iran
  3. 3. Heart Failure Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT, United States
  5. 5. Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Heart Failure Reviews Published:2021


Abstract

Heart failure (HF) is a major consequence of many cardiovascular diseases with high rate of morbidity and mortality. Early diagnosis and prevention are hampered by the lack of informative biomarkers. The aim of this study was to perform a meta-analysis of the miRNA expression profiling studies in HF to identify novel candidate biomarkers or/and therapeutic targets. A comprehensive literature search of the PubMed for miRNA expression studies related to HF was carried out. The vote counting and robust rank aggregation meta-analysis methods were used to identify significant meta-signatures of HF-miRs. The targets of HF-miRs were identified, and network construction and gene set enrichment analysis (GSEA) were performed to identify the genes and cognitive pathways most affected by the dysregulation of the miRNAs. The literature search identified forty-five miRNA expression studies related to CHF. Shared meta-signature was identified for 3 up-regulated (miR-21, miR-214, and miR-27b) and 13 down-regulated (miR-133a, miR-29a, miR-29b, miR-451, miR-185, miR-133b, miR-30e, miR-30b, miR-1, miR-150, miR-486, miR-149, and miR-16-5p) miRNAs. Network properties showed miR-29a, miR-21, miR-29b, miR-1, miR-16, miR-133a, and miR-133b have the most degree centrality. GESA identified functionally related sets of genes in signaling and community pathways in HF that are the targets of HF-miRs. The miRNA expression meta-analysis identified sixteen highly significant HF-miRs that are differentially expressed in HF. Further validation in large patient cohorts is required to confirm the significance of these miRs as HF biomarkers and therapeutic targets. © 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.
Other Related Docs
20. Exploring Conserved Mrna-Mirna Interactions in Colon and Lung Cancers, Gastroenterology and Hepatology from Bed to Bench (2017)
21. Microrna: Relevance to Stroke Diagnosis, Prognosis, and Therapy, Journal of Cellular Physiology (2018)
24. Micrornas As the Actors in the Atherosclerosis Scenario, Journal of Physiology and Biochemistry (2020)
27. Microrna Profiles in Critically Ill Patients, Current Medicinal Chemistry (2024)
32. Mir-193B Deregulation Is Associated With Parkinson's Disease, Journal of Cellular and Molecular Medicine (2021)
36. Micrornas in Female Infertility: An Overview, Cell Biochemistry and Function (2021)
38. How Are Epigenetic Modifications Related to Cardiovascular Disease in Older Adults?, International Journal of Molecular Sciences (2021)
39. Role of Micrornas in Pulmonary Hypertension, Horizons in World Cardiovascular Research (2022)
40. A Review on Expression and Regulatory Mechanisms of Mir-337-3P in Cancer, Journal of Biomolecular Structure and Dynamics (2024)
47. Mir-802-5P Is a Key Regulator in Diabetic Kidney Disease, Journal of Research in Medical Sciences (2023)
48. Modulation of Micrornas by Aspirin in Cardiovascular Disease, Trends in Cardiovascular Medicine (2020)
50. Circular Rnas: A Small Piece in the Heart Failure Puzzle, Functional and Integrative Genomics (2024)